Features | Partner Sites | Information | LinkXpress
Sign In
GLOBETECH PUBLISHING LLC
GLOBETECH PUBLISHING LLC
GLOBETECH MEDIA

Gene Variations Can Predict Radiation-Induced Toxicity Risk

By BiotechDaily International staff writers
Posted on 04 Aug 2014
Key genetic variants may affect how cancer patients respond to radiation treatments, according to new research. Scientists discovered that differences in the TANC1 (tetratricopeptide repeat, ankyrin repeat and coiled-coil containing 1) gene are associated with a greater risk for radiation-fueled side effects in prostate cancer patients, which include impotence, diarrhea, and incontinence.

These findings, published July 2014 in Nature Genetics, are based on a genome-wide association study, a type of study in which researchers studied a variety of genetic variants to see if any of them are tied to a specific type of complication, which could sometimes appear years after treatment was completed.

“Our findings, which were replicated in two additional patient groups, represent a significant step towards developing personalized treatment plans for prostate cancer patients,” said Barry S. Rosenstein, PhD, professor, radiation oncology, genetics and genomic sciences, Icahn School of Medicine at Mount Sinai (New York, NY, USA), the lead Mount Sinai investigator on the study. “Within five years, through the use of a predictive genomic test that will be created using the data obtained in the recent study, it may be possible to optimize treatment for a large number of cancer patients.”

For the study, Dr. Rosenstein and his colleagues obtained blood samples from nearly 400 patients who were receiving radiotherapy treatment for prostate cancer. The blood samples were screened for roughly one million genetic markers, and each patient was monitored for at least two years to monitor incidents of side effects from the radiation. Data analysis revealed which genetic markers were consistently associated with the development of complications following radiotherapy.

“The next step is to validate the results, and see if the same markers predict similar outcomes in patients with other forms of cancer,” said Dr. Rosenstein. Using the genomic test being developed, treatment plans can be adjusted to curtail adverse effects thereby allowing for an improved quality life for many cancer survivors.

Related Links:

Icahn School of Medicine at Mount Sinai



Channels

Drug Discovery

view channel
Image: Star-like glial cells in red surround alpha-beta plaques in the cortex of a mouse with a model of Alzheimer\'s disease (Photo courtesy of Strittmatter laboratory/Yale University).

Experimental Cancer Drug Reverses Symptoms in Mouse Model of Alzheimer's Disease

An experimental, but clinically disappointing drug for treatment of cancer has been found to be extremely effective in reversing the symptoms of Alzheimer's disease (AD) in a mouse model.... Read more

Biochemistry

view channel
Image:  Model depiction of a novel cellular mechanism by which regulation of cryptochromes Cry1 and Cry2 enables coordination of a protective transcriptional response to DNA damage caused by genotoxic stress (Photo courtesy of the journal eLife, March 2015, Papp SJ, Huber AL, et al.).

Two Proteins Critical for Circadian Cycles Protect Cells from Mutations

Scientists have discovered that two proteins critical for maintaining healthy day-night cycles also have an unexpected role in DNA repair and protecting cells against genetic mutations that could lead... Read more

Business

view channel

NanoString and MD Anderson Collaborate on Development of Novel Multi-Omic Expression Profiling Assays for Cancer

The University of Texas MD Anderson Cancer Center (Houston, TX, USA) and NanoString Technologies, Inc. (Seattle, WA, USA) will partner on development of a revolutionary new type of assay—simultaneously profiling gene and protein expression, initially aiming to discover and validate biomarker signatures for immuno-oncology... Read more
 
Copyright © 2000-2015 Globetech Media. All rights reserved.